AI Driven Precision Medicine
We are leveraging our full-stack Bio-AI platform to improve outcomes for cancer and neurology patients across the continuum of care, from screening through to diagnosis and treatment.
AI is rewriting the rules of disease research
Accelerating insights, personalizing treatments, and bringing us closer to a world where every patient’s cure is just a discovery away. Harnessing the power of deep learning and predictive analytics, we can uncover hidden patterns in complex data, revolutionizing how we detect, treat, and ultimately defeat disease.
Tomorrow’s treatments aren’t one-size-fits-all
Precision medicine is about delivering the right therapy to the right patient at the right time. By combining big data, genomic insights, and advanced analytics, we’re transforming medicine to ensure every individual gets the most effective, personalized care possible.
The Renovaro Timeline
August 2023
Renovaro launches to develop cell,
gene, and immunotherapies
gene, and immunotherapies
Renovaro begins as a therapeutics company specializing in the genetic modification of dendritic cells to fight cancer and immune-mediated diseases.
September 2023
GEDiCube identifies 10K
cancer-specific biomarkers
cancer-specific biomarkers
GEDiCube, an Amsterdam-based technology startup uses proprietary algorithms to identify 10K plus biomarkers spanning 13 cancer types.
February 2024
Merger between Renovaro
and GEDiCube
and GEDiCube
GEDiCube is officially acquired by Renovaro in a stock-for-stock acquisition; GEDiCube is rebranded as Renovaro Cube, and LA-based Renovaro is rebranded as Renovaro Biosciences.
December 2024
Renovaro receives LUMINA grant
Renovaro receives grant approval for LUMINA project to develop advanced minimal residual disease detection platform for lung cancer from the Eurostars funding program.
February 2025
Renovaro receives 15M
in equity committed
in equity committed
Renovaro fundraising results in 15M in equity to advance its AI-driven cancer diagnostics and therapeutic development programs.
April 2025
Renovaro merges with BioSymetrics
Renovaro acquires New York based BioSymetrics, a translational medicine company.
May 2025
Renovaro releases Augusta for precision neurology
Combining components of our Cube technology with BioSymetrics’ Phenograph and In Vivo validation, Augusta is a unique platform for neurological disease diagnosis and therapeutic development.
